Floyd Petersen Sells 16,679 Shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Floyd Petersen sold 16,679 shares of the firm’s stock in a transaction that occurred on Thursday, November 13th. The stock was sold at an average price of $26.49, for a total transaction of $441,826.71. Following the transaction, the director directly owned 75,531 shares of the company’s stock, valued at $2,000,816.19. This represents a 18.09% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Amphastar Pharmaceuticals Stock Down 0.5%

AMPH stock opened at $25.90 on Wednesday. The company has a market capitalization of $1.19 billion, a P/E ratio of 9.70 and a beta of 0.77. Amphastar Pharmaceuticals, Inc. has a 12 month low of $20.39 and a 12 month high of $46.43. The firm’s fifty day simple moving average is $25.78 and its 200-day simple moving average is $25.40. The company has a debt-to-equity ratio of 0.80, a current ratio of 3.29 and a quick ratio of 2.21.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its earnings results on Thursday, November 6th. The company reported $0.93 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.83 by $0.10. Amphastar Pharmaceuticals had a net margin of 18.64% and a return on equity of 20.76%. The firm had revenue of $191.84 million during the quarter, compared to analysts’ expectations of $186.90 million. As a group, equities research analysts forecast that Amphastar Pharmaceuticals, Inc. will post 3.49 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on AMPH shares. Needham & Company LLC lowered their target price on Amphastar Pharmaceuticals from $36.00 to $34.00 and set a “buy” rating on the stock in a research note on Friday, November 7th. Piper Sandler lowered their price objective on Amphastar Pharmaceuticals from $30.00 to $25.00 and set a “neutral” rating on the stock in a research report on Friday, August 8th. Bank of America raised their price objective on shares of Amphastar Pharmaceuticals from $28.00 to $32.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 26th. Weiss Ratings reiterated a “hold (c)” rating on shares of Amphastar Pharmaceuticals in a research note on Monday. Finally, Zacks Research downgraded shares of Amphastar Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, November 14th. Two analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Amphastar Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $31.20.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its stake in Amphastar Pharmaceuticals by 5.2% during the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 9,440 shares of the company’s stock worth $217,000 after purchasing an additional 465 shares during the period. Signaturefd LLC increased its stake in Amphastar Pharmaceuticals by 147.7% during the 1st quarter. Signaturefd LLC now owns 872 shares of the company’s stock worth $25,000 after buying an additional 520 shares during the period. Illumine Investment Management LLC lifted its holdings in Amphastar Pharmaceuticals by 2.0% during the 3rd quarter. Illumine Investment Management LLC now owns 27,677 shares of the company’s stock worth $738,000 after buying an additional 551 shares in the last quarter. Advisory Research Inc. lifted its holdings in Amphastar Pharmaceuticals by 3.8% during the 3rd quarter. Advisory Research Inc. now owns 15,468 shares of the company’s stock worth $412,000 after buying an additional 570 shares in the last quarter. Finally, State of Wyoming boosted its position in Amphastar Pharmaceuticals by 21.2% in the 3rd quarter. State of Wyoming now owns 3,301 shares of the company’s stock valued at $88,000 after buying an additional 578 shares during the period. 65.09% of the stock is owned by institutional investors and hedge funds.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.